Form 4: IMMUNIC, INC. Director Acquires Stock Options

Director Michael W. Bonney acquired 100,000 stock options for IMMUNIC, INC. (IMUX) on June 29, 2026, as part of a plan approved by the Board of Directors and stockholders.

Summary

• Michael W. Bonney, a Director at IMMUNIC, INC. (IMUX), acquired 100,000 stock options on June 29, 2026.
• These options are for the purchase of common stock at an exercise price of $12.08 per share.
• The options were conditionally approved by the Board of Directors on May 15, 2026, and subsequently approved by stockholders at the 2026 Annual Meeting on June 29, 2026.
• The options are set to vest in thirty-six equal monthly installments starting from May 15, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director compensation and incentive mechanism rather than a significant operational or financial event.

Positives

• Director acquisition of stock options indicates confidence in the company's future prospects.
• The transaction was made pursuant to a 10b5-1(c) plan, suggesting a pre-determined and structured approach to equity transactions.
• Stockholder approval of the equity incentive plan amendment demonstrates alignment between management and shareholders.

Risks

• The options are subject to vesting over 36 months, meaning immediate full ownership is not granted.
• The exercise price of $12.08 per share implies that the stock price needs to appreciate significantly for the options to be profitable.
• The approval of the equity plan amendment by stockholders is a condition for the options, though this condition has now been met.

Future Outlook

The acquisition of stock options by a director, coupled with stockholder approval of the equity plan, suggests a positive outlook and alignment with long-term company performance.

Industry Context

StockSavvy.ai notes that director stock option grants are a common incentive in the biotechnology and pharmaceutical sectors, aligning executive interests with shareholder value creation and long-term growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with long-term stock performance, potentially leading to increased shareholder value if the stock price appreciates.
• Employees: The approved equity incentive plan provides a framework for future employee compensation, potentially boosting morale and retention.

Next Steps

• The stock options will vest over 36 months, starting from May 15, 2026.
• The company's equity incentive plan amendment, approved by stockholders, will be effective.

Key Dates

Keywords

IMMUNIC, INC., IMUX, Form 4, Stock Options, Director, Beneficial Ownership, Equity Incentive Plan, Michael W. Bonney